Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Basit Öğe Kaydı
dc.contributor.authorKoklu, Seyfettin
dc.contributor.authorKoksal, Iftihar
dc.contributor.authorAkarca, Ulus Salih
dc.contributor.authorBalkan, Ayhan
dc.contributor.authorGuner, Rahmet
dc.contributor.authorDemirezen, Aylin
dc.contributor.authorSahin, Memduh
dc.contributor.authorAkhan, Sila
dc.contributor.authorOzaras, Resat
dc.contributor.authorIdilman, Ramazan
dc.date.accessioned2019-10-27T11:22:17Z
dc.date.available2019-10-27T11:22:17Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim. To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. Material and methods. Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early access program. Most of the patients were in difficult-to-treat category. Patients were visited at each 4 week throughout the follow-up period. Laboratory findings and adverse events were recorded at each visit. Results. Fifty-seven of 61 enrolled patients completed 24 weeks of treatment. Two patients died as a result of underlying diseases at 12-14th weeks of treatment. Two patients stopped the treatment early as a consequence of virological breakthrough, and 2 patients had viral relapse at the post-treatment follow-up. Overall SVR12 rates were 90% (55/61) and 93.2% (55/59) according to intention-to-treat (ITT) and per protocol (PP) analysis respectively. In ITT analysis, SVR12 was achieved by 93% (13/14) in relapsers, 80% (12/15) in interferon-ineligible patients and 91% (20/22) in previous nonresponder patients. SVR12 rates were 86.5% and 91.4% in patients with cirrhosis according to ITT and PP analysis respectively. SVR12 was 95.8% in non-cirrhosis group in both analysis. Patients with previous protease inhibitor experience had an SVR12 of 87.5%. Common adverse events developed in 28.8% of patients. There were no treatment related severe adverse event or grade-4 laboratory abnormality. Conclusions. Daclatasvir and asunaprevir dual therapy is found to be effective and safe in difficult-to-treat Turkish patients with HCV genotype 1b infection.en_US
dc.identifier.doi10.5604/16652681.1226817
dc.identifier.endpage76en_US
dc.identifier.issn1665-2681
dc.identifier.issn1665-2681en_US
dc.identifier.issue1en_US
dc.identifier.startpage71en_US
dc.identifier.urihttps://doi.org/10.5604/16652681.1226817
dc.identifier.urihttps://hdl.handle.net/11454/33014
dc.identifier.volume16en_US
dc.identifier.wosWOS:000397078000011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMexican Assoc Hepatologyen_US
dc.relation.ispartofAnnals of Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic C hepatitisen_US
dc.subjectDaclatasviren_US
dc.subjectAsunapreviren_US
dc.titleDaclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Programen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu